Provention Bio Inc., of Oldwick, N.J., aims to raise between $40 million and $50 million in a best-efforts IPO. The company said its mission is to in-license, transform and develop clinical-stage, or nearly clinical-stage, therapeutic candidates targeting type 1 diabetes, Crohn's disease, ulcerative colitis, lupus and life-threating viral diseases.